| 1.15 0.05 (4.55%) | 10-20 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 1.91 | 1-year : | 2.31 |
| Resists | First : | 1.63 | Second : | 1.98 |
| Pivot price | 1.27  |
|||
| Supports | First : | 1.08 | Second : | 0.89 |
| MAs | MA(5) : | 1.12 |
MA(20) : | 1.38 |
| MA(100) : | 1.43 |
MA(250) : | 1.24 |
|
| MACD | MACD : | -0.2 |
Signal : | -0.2 |
| %K %D | K(14,3) : | 5.2 |
D(3) : | 3.5 |
| RSI | RSI(14): 26.6 |
|||
| 52-week | High : | 2.33 | Low : | 0.87 |
Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.[ CRDL ] has closed above bottom band by 30.3%. Bollinger Bands are 39.1% wider than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 1.17 - 1.18 | 1.18 - 1.18 |
| Low: | 1.08 - 1.08 | 1.08 - 1.09 |
| Close: | 1.14 - 1.15 | 1.15 - 1.16 |
Cardiol Therapeutics Inc. is a clinical-stage life sciences firm dedicated to discovering and advancing anti-fibrotic and anti-inflammatory therapies for cardiovascular disease (CVD). Its leading candidate, CardiolRx, is currently undergoing a multi-national, randomized, double-blind, placebo-controlled Phase II/III study. This pivotal trial assesses CardiolRx's safety and effectiveness as a cardioprotective treatment to diminish cardiovascular and respiratory complications in hospitalized COVID-19 patients, while also investigating its potential for acute myocarditis. Furthermore, the company is developing a subcutaneous version of CardiolRx, aimed at addressing the cardiac fibrosis and inflammation linked to the onset and progression of heart failure. Cardiol Therapeutics Inc. was established in 2017 and operates from its headquarters in Oakville, Canada.
Wed, 21 Oct 2026
Cardiol Therapeutics Inc. Class A (TSX:CRDL) Extends Positive Momentum as Investor Optimism Strengthens - kalkine.ca
Mon, 28 Sep 2026
Tejara Capital Ltd Expands Stake in Cardiol Therapeutics Inc (CR - GuruFocus
Sat, 12 Sep 2026
Cardiol Therapeutics: Q1 2027 Readout Will Be Make-Or-Break For MAVERIC (NASDAQ:CRDL) - Seeking Alpha
Wed, 26 Aug 2026
B.Riley initiates Cardiol Therapeutics stock with buy rating on pericarditis drug potential - Investing.com
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Outperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Drug Manufacturers - Specialty & Generic
|
|
| Shares Out | 122 (M) |
| Shares Float | 92 (M) |
| Held by Insiders | 2.2 (%) |
| Held by Institutions | 26.3 (%) |
| Shares Short | 3,070 (K) |
| Shares Short P.Month | 2,930 (K) |
| EPS | -0.25 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0.15 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -91 % |
| Return on Equity (ttm) | -190.2 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | -0.3 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -24 (M) |
| Levered Free Cash Flow | -15 (M) |
| PE Ratio | -4.6 |
| PEG Ratio | 0 |
| Price to Book value | 7.66 |
| Price to Sales | 0 |
| Price to Cash Flow | -5.82 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|